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Abstract
Background The gut hormones are important in regulat-
ing gastrointestinal motility. Disturbances in gastrointesti-
nal motility have been reported in patients with irritable
bowel syndrome (IBS). Reduced endocrine cell density, as
revealed by chromogranin A, has been reported in the
colon of IBS patients.
Aims To investigate a possible abnormality in the colonic
endocrine cells of IBS patients.
Methods A total of 41 patients with IBS according to
Rome Criteria III and 20 controls were included in the
study. Biopsies from the right and left colon were obtained
from both patients and controls during colonoscopy. The
biopsies were immunostained for serotonin, peptide YY
(PYY), pancreatic polypeptide (PP), entroglucagon, and
somatostatin cells. Cell densities were quantified by com-
puterized image analysis.
Results Serotonin and PYY cell densities were reduced in
the colon of IBS patients. PP, entroglucagon, and soma-
tostatin-immunoreactive cells were too few to enable reli-
able quantification.
Conclusion The cause of these observations could be
primary genetic defect(s), secondary to altered serotonin
and/or PYY signaling systems and/or subclinical inflam-
mation. Serotonin activates the submucosal sensory branch
of the enteric nervous system and controls gastrointestinal
motility and chloride secretion via interneurons and motor
neurons. PYY stimulates absorption of water and electro-
lytes, and inhibits prostaglandin (PG) E2, and vasoactive
intestinal peptide, which stimulates intestinal fluid secre-
tion and is a major regulator of the ‘‘ileal brake’’. Although
the cause and effect relationship of these findings is diffi-
cult to elucidate, the abnormalities reported here might
contribute to the symptoms associated with IBS.
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Introduction
Irritable bowel syndrome (IBS) is a gastrointestinal chronic
disorder which is characterized by abdominal discomfort or
pain associated with altered bowel habits, and often bloating
and abdominal distension [1, 2]. The degree of symptoms
varies in different patients from tolerable to severe, with a
considerable reduction of quality of life and productivity
[1–5]. This disorder affects 10–15% of the western popula-
tion with female predominance [1, 2]. Besides the increased
morbidity caused by IBS, it is an economic burden to society
in different indirect forms, for example increased sick leave
and over-consumption of healthcare resources [6, 7].
Disturbances of gastrointestinal motility have been
reported in patients with IBS [8–14]. It has been speculated
that this dysmotility is caused by genetic and psychosocial
factors, and stress [6, 7]. The gastrointestinal tract hormones
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are important in regulating gastrointestinal motility [15].
Few studies have been conducted on gut hormones in IBS
patients [16–23]. These studies concentrated mostly on
serotonin [16–19].
In a previous study, the density of chromogranin A was
reduced in the colon of patients with IBS [24]. Chromogranin
A is a general marker for all endocrine cells. This finding
raises the question as to which endocrine cell type is affected
in the colon. Thus, this study was undertaken to discover the
endocrine cell type(s) affected in the colon of IBS patients.
Materials and Methods
Patients and Controls
Forty-one patients with irritable bowel syndrome that fulfilled
Rome Criteria III using the IBS module were included in the
study [25, 26]. These patients were 39 females and two males
with an average age of 35 years (range 18–58 years).
Twenty-three patients had diarrhea (IBS-diarrhea) and 18
patients had constipation (IBS-constipation) as the predomi-
nant symptom. All patients underwent a complete physical
examination and were investigated by means of blood tests
(full blood count, electrolytes, calcium, and inflammatory
markers), liver tests, and thyroid function tests.
Twenty subjects that underwent colonoscopy with
biopsies were used as controls. Twelve of these subjects
underwent colonoscopy because of gastrointestinal bleed-
ing, where the source of bleeding was identified as hem-
orrhoids, and eight subjects because of health worries
caused by a relative(s) having been diagnosed with colon
carcinoma. These subjects were 13 females and seven
males with an average age of 49 years (range 24–66 years).
The study was performed in accordance with the Dec-
laration of Helsinki and was approved by the local Com-
mittee for Medical Research Ethics. All subjects gave oral
and written consent.
Colonoscopy
Colonoscopy was performed on patients and controls, and two
biopsies were taken from the cecum, from the ascending
colon, and from the right half of the transverse colon. All six
biopsies were pooled and used as the right colon. Moreover,
two biopsies were taken from the left half of the transverse
colon, from the descending colon, and from the sigmoid colon.
These six biopsies were pooled and used as the left colon.
Histopathology and Immunohistochemistry
Biopsies were fixed overnight in 4% buffered paraformal-
dehyde, embedded in paraffin, and cut into 5-lm sections.
The sections were stained with hematoxylin–eosin and
immunostained by use of the avidin–biotin complex (ABC)
method using the Vectastain ABC kit (Vector Laborato-
ries) as described in detail elsewhere [27]. The primary
antibodies used were: monoclonal mouse anti-serotonin
(DakoCytomation, code no. 5HT-209), polyclonal anti-
porcine peptide YY (PYY; Alpha-diagnostica, code PYY
11A), polyclonal rabbit anti-synthetic human pancreatic
polypeptide (PP; Diagnostic Biosystems, code no. #114),
polyclonal rabbit anti-porcine glicentin/glucagon (Acris
Antibodies, code BP508), and polyclonal rabbit anti-syn-
thetic human somatostatin (DakoCytomation, code no.
A566). The antibodies were used at dilutions of 1:1,500,
1:1,000, 1:800, 1:400, and 1:200, respectively. The second
layer biotinylated mouse anti-IgG and rabbit anti-IgG were
obtained from DakoCytomation. Negative and positive
controls were the same as those described elsewhere [27].
Anti-PYY cross-reacted \0.001% with neuropeptide Y
(NPY) in the radioimmunoassay system.
Computerized Image Analysis
Numbers of immunoreactive cells and areas of the epi-
thelial cells were measured by use of the Olympus soft-
ware: Cell^D. The 940 objective was used, so the frame
(field) on the monitor represented an area of 0.14 mm2 of
the tissue in each field. Each individual and peptide hor-
mone was measured in 10 randomly chosen fields. Immu-
nostained sections from IBS patients and controls were
coded and mixed, and measurements were made without
knowledge of the identity of the sections. The data from the
fields were tabulated; the number of cells/mm2 of the
epithelium was computed and statistically analyzed
automatically.
Statistical Analysis
The Kruskal–Wallis non-parametric ANOVA test and
Dunn‘s post-test were used. P values \0.05 were consid-
ered significant.
Results
Endoscopy, Histopathology,
and Immunohistochemistry
The colons of patients and control subjects were macro-
scopically normal.
Histopathological examination of the colon biopsies
from patients and controls revealed normal histology,
except for four controls and five patients, where
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nonspecific inflammation was found. In the colon of
patients and control subjects, serotonin, PYY, PP, entrog-
lucagon, and somatostatin-immunoreactive cells were
found, mostly in the upper part of the crypts of Lieberku¨hn.
These cells were basket or flask-shaped (Figs. 1, 2).
Computerized Image Analysis
PP, entroglucagon, and somatostatin-immunoreactive cells
were too few in the biopsy material examined. This made it
difficult to quantify these cell types reliably.
There was no statistically significant difference between
the right and left colon in controls regarding densities of
serotonin and PYY-immunoreactive cells (P = 0.9 and
0.1, respectively).
Serotonin cell density was reduced in the colon of IBS
patients (Figs. 1, 3). This reduction was found in both IBS-
diarrhea and IBS-constipation patients. In the right colon,
serotonin cell density in IBS patients as a whole and in both
sub-types was lower than in controls (Fig. 3). In the left
colon, serotonin cell density was reduced in IBS patients as
a whole and in IBS-diarrhea patients, but not in those with
IBS-constipation (Fig. 3).
PYY cell density was lower than controls in the colon as
a whole and in the right and left colon. PYY cell density
was reduced also in both sub-types of IBS (Figs. 2, 4).
Discussion
The age and sex of the patients and control subjects used in
this investigation did not match completely. The control
subjects are slightly older and the proportion of males to
females is higher. In previous studies, however, age and
gender have been found to have no effect on the density of
intestinal endocrine cells in adults [28, 29]. Different
topographic distribution of large intestinal endocrine cell
densities has previously been reported [30]. Thus, in this
investigation endocrine cell densities were studied in dif-
ferent segments of the colon.
Fig. 1 Serotonin-immunoreactive cells in the colon of a healthy
volunteer (a) and of a patient with IBS (b)
Fig. 2 PYY-immunoreactive cells in the colon of a healthy volunteer
(a) and of a patient with IBS-diarrhea (b)
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This study showed that serotonin and PYY cell densities
were reduced in both sub-types of IBS, i.e. IBS-diarrhea
and IBS-constipation. It is noteworthy, however, that in the
left colon of patients with IBS-constipation, serotonin cell
density was not statistically significant. One cannot exclude
the possibility this was a type II statistical error; however,
in a previous report chromogranin A cell density was also
not significant in the same segment of the colon of the same
patient group [24]. Mucosal 5-HT concentration has been
reported to be low in IBS patients [31], in agreement with
our observation. Previous studies of patients with post-
infectious IBS (PI-IBS) of the diarrhea-predominant type
have shown however, that the number of serotonin cells
increased in the rectum [16, 19, 32, 33]. Our finding that
serotonin cell density was reduced in the colon raises the
possibility that PI-IBS and sporadic IBS can have a dif-
ferent pathophysiology. One should also point out that the
rectum harbors a larger number of endocrine cells than the
colon [30].
The low densities of serotonin and PYY cells in IBS
patients found here could be primary or secondary to other
pathological process. Thus, the cause of these observations
could be primary genetic defect(s), secondary to altered
serotonin and/or PYY signaling systems and/or subclinical
inflammation. It is not known whether a defect occurs in
the genes controlling the expression of serotonin and PYY.
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Fig. 3 Density of serotonin cells in the colon in IBS patients and as a
whole and in the two subtypes of IBS (a), in the right colon (b), and in
the left colon (c). Statistical significance expressed as comparison
between controls and IBS patients and subtypes. **P \ 0.01 and
***P \ 0.001
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Fig. 4 PYY cell density in the colon in IBS patients and as a whole
and in the two subtypes of IBS (a), in the right colon (b), and in the
left colon (c). Statistical significance expressed as in Fig. 3
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However, an association between a functional polymor-
phism in the serotonin transporter (SERT) gene and
diarrhea-predominant IBS has been reported [34, 35].
Furthermore, it has been reported that tryptophan hydrox-
ylase 1 messenger RNA, serotonin transport messenger
RNA, and serotonin transport immunoreactivity all are
reduced in IBS patients [31]. It is possible that the obser-
vation made here on serotonin is secondary to SERT gene
polymorphism and/or an altered 5-HT signaling system. It
has been proposed that low-grade inflammation might be
responsible for symptoms in at least a subset of IBS suf-
ferers [36, 37]. It is possible that the abnormality observed
here is caused by a colonic submucosal low-grade
inflammation. In support of this assumption is the obser-
vation that serotonin secretion by enterochromaffin (EC)
cells can be enhanced or attenuated by secretory products
of immune cells, for example CD4?T [38]. Furthermore,
serotonin modulates the immune response [38]. The EC
cells are in contact with or very close to CD3? and CD20?
lymphocytes and several sertotongeric receptors have been
characterized in lymphocytes, monocytes, macrophages,
and dendrtic cells [38, 39]. It has been reported that IBS-
diarrhea patients have a significantly higher prevalence of
macroscopic mucosal colonic erythema, with ‘‘nonspe-
cific’’ inflammation being observed for a significant pro-
portion of these patients on histopathological evaluation
[35]. The authors argued, however, that their findings
might be explained by an ascertainment bias [35]. The
occurrence of colonic mucosal nonspecific inflammation in
the IBS patients investigated in this study did not differ
from that of healthy controls.
It is rather interesting that patients with IBS sub-types
had the same abnormalities in serotonin and PYY cells.
Previous studies have shown that IBS-diarrhea and IBS-
constipation have the same abnormality in the serotonin
signaling system [31]. Actually, IBS patients are charac-
terized basically by altered bowel habits. Dividing IBS
patients into subtypes based on predominance of diarrhea
or constipation is a clinical classification to facilitate
clinical symptomatic management. It is possible, therefore,
that IBS patients, irrespective of subtype, share the same
pathophysiology.
Serotonin activates the submucosal sensory branch of
the enteric nervous system and controls gastrointestinal
motility and chloride secretion via interneurons and motor
neurons [40, 41]. PYY stimulates absorption of water and
electrolytes and is a major regulator of the ‘‘ileal brake’’
[42]. Furthermore, PYY inhibits prostaglandin (PG) E2 and
vasoactive intestinal peptide, which stimulate intestinal
fluid secretion [43–45]. Administration of PYY inhibits
diarrhea in experimental mouse models by reducing
intestinal fluid secretion and slowing colonic transit [46].
Although the cause and effect relationship of our findings
is difficult to elucidate, the abnormalities reported here
might contributes to the symptoms associated with IBS.
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